Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials

Heart failure is frequently associated with diabetes, and therapies which reduce mortality in people with heart failure and reduced ejection fraction (HFrEF) are often limited to drugs which modulate the renin–angiotensin–aldosterone system or heart rate control and occasionally to device therapy. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, David M., Evans, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434820/
https://www.ncbi.nlm.nih.gov/pubmed/32710261
http://dx.doi.org/10.1007/s13300-020-00889-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434820/
https://www.ncbi.nlm.nih.gov/pubmed/32710261
http://dx.doi.org/10.1007/s13300-020-00889-9

Ejemplares similares